The FDA has approved a label update for Eli Lilly’s Kisunla, an Alzheimer’s treatment, by modifying the recommended dosing schedule for adults with early symptomatic Alzheimer’s disease.
The update introduces a gradual titration schedule aimed at reducing risk of amyloid-related imaging abnormalities with edema, a known side effect of amyloid plaque-targeting therapies, according to a July 9 news release from the drugmaker. In a recent study, patients receiving the modified dosing experienced significantly fewer events, 14% at 24 weeks and 16% at 52 weeks compared to 24% and 25%, respectively, among patients on the original dosing schedule.
Kisunla, approved in 2024, is administered once monthly and designed for limited-duration use depending on plaque removal. The therapy is meant for patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
